
WilmerHale Represents Fulcrum Therapeutics in Series A Financing from GV

MAY 10, 2017

Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, announced that it has secured additional Series A funding from GV (formerly Google Ventures) to support the continued advancement of its lead programs in Fragile X syndrome and Fascioscapularhumeral muscular dystrophy.

The WilmerHale team representing Fulcrum Therapeutics includes [Lia Der Marderosian](#), [Stephanie Singer](#) and [Byron Crowe](#).

Read Fulcrum Therapeutics' [press release](#) for more information.